ReCAPSE: Recurrence from Claims And PROs for SEER Enhancement

ReCAPSE：SEER 增强的索赔和 PRO 的复发

• 批准号: 10428568
• 负责人: Jessica Chubak
• 金额: $ 56.77万
• 依托单位: FRED HUTCHINSON CANCER CENTER
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-25 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10428568
• 关键词: Accounting; Address; Agreement; Algorithms; Area; Breast Cancer Patient; Cancer Burden; Cancer Center; Cancer Survivor; Clinical; Collaborations; Computerized Medical Record; Confidentiality of Patient Information; Controlled Clinical Trials; Data; Diagnosis; Disease; Disease Management; Disease remission; Electronic Health Record; Enrollment; Environment; Event; Frequencies; Future; Glare; Goals; Gold; Health Insurance; Health Maintenance Organizations; Health Technology; Incidence; Individual; Insurance; Intervention; Kentucky; Lead; Link; Malignant Neoplasms; Medical; Medical Records; Medicare; National Cancer Institute; Outcome; Participant; Patient Outcomes Assessments; Patient Representative; Patient Self-Report; Patients; Pattern; Performance; Phase; Policies; Population; Prevalence; Provider; Quality Indicator; Quality of life; Recording of previous events; Records; Recurrence; Registries; Reproducibility; Research; Resources; Risk; SEER Program; Sampling; Science; Site; Specific qualifier value; Specificity; Subgroup; System; Technology; Time; Treatment/Psychosocial Effects; Universities; Validation; Vision; Visual; Woman; Work; base; breast cancer diagnosis; cancer recurrence; cancer therapy; case control; cohort; cost; dashboard; data quality; data registry; design; effectiveness study; experience; flexibility; implementation tool; improved; innovation; insurance claims; malignant breast neoplasm; mobile application; mortality; multidisciplinary; neoplasm registry; neoplasm resource; novel; patient health information; population based; population health; preservation; prevent; prognostic; sound; statistics; tool; tool development; tumor

PROJECT SUMMARY The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute serves as a national dashboard for cancer surveillance and is an authoritative resource for cancer incidence and mortality rates. However, the registry lacks information on cancer recurrence, which is a major outcome impacting decisions and policies around management of disease at both the individual and the population levels. The goal of the proposed study is to develop a scalable approach for population-based ascertainment of cancer recurrence with a specific focus on breast cancer. The first (UG3) phase of the study will develop an innovative algorithm for detecting a first recurrence by combining medical claims with patient reported outcomes (PROs). This phase will be conducted in collaboration with the Seattle-Puget Sound SEER registry and will leverage ongoing research agreements with Puget Sound payers. Different algorithms will be developed to allow for flexibility in maximizing sensitivity or specificity. The algorithms will be validated against gold-standard recurrence information based on electronic medical records from two major local providers. Study participants will consistent of stage I-III breast cancer patients diagnosed in 2013–2016 on whom “gold standard” information on recurrence is available. A retrospective case-control design will be employed in which an equal number of recurrent cases and non-recurrent controls at each validation site will be solicited for PROs regarding their recurrence histories. All validation activities will explicitly adjust for missing data resulting from participant non-response to the PRO solicitation. The second (UH3) phase will be conducted in collaboration with the Kentucky Cancer Registry. The algorithms developed in the UG3 phase will be deployed on all Kentucky stage I-III breast cancer diagnoses in 2015–2017 on whom claims data are available. This phase will include a validation against medical records from patients diagnosed at the University of Kentucky Markey Cancer Center over a concurrent period. In this phase, the study team will develop a visual interface for summarizing recurrence risks overall and within specified prognostic subgroups. The interface will allow users to examine representativeness of the patient cohort used to estimate recurrence risks and will also provide estimates that are adjusted for participant non-response. The proposed work will represent a pioneering effort that establish whether medical claims data combined with patient self-report constitute a promising avenue towards determining whether the critical endpoint of cancer recurrence can be added to population-based cancer registries.

项目摘要 国家癌症研究所的监视，流行病学和最终结果（SEER）计划 作为癌症监测的纳什板，是癌症的权威资源 然而，发病率和刻痕率缺乏有关癌症的信息 影响疾病管理的决定和政策的主要结果 个人和人口水平。 用于癌症复发的人口，对乳腺癌进行了特定的重点 研究的第一阶段（UG3）阶段将一种用于检测第一次复发的企业算法 将医疗索赔与患者报告的结果（专业）结合起来。 与Search-Puget Sound Seer注册表和Wartage正在进行的研究 与Puget Sound付款人的协议将开发出来的算法 最大化灵敏度或特异性。 基于两个主要提供者的电子病历 将在2013 - 2016年诊断出的I-IIII期乳腺癌患者一致 有关复发的信息可用。 每个验证站点处的递归数量和非循环控制都将被征集 对于复发历史的专业人士，所有验证活动都会明确调整 参与者对PRO解决方案（UH3）阶段无反应产生的数据将是 与Tucky Cancer注册中心合作进行。 阶段将在2015 - 2017年的所有肯塔基州I-III阶段乳腺癌诊断中部署 索赔数据可用。 在此期间，在肯塔基大学Markey Cancer Central诊断出 阶段，研究团队将视觉界面定为总结整体上的递归风险，并且 在指定的程序中，该接口将允许用户检查 患者队列用于估计复发风险，Wilso提供了经过调整的估计值 对于参与者无响应。 医疗索赔数据是否结合患者自我报告征兵是有希望的途径 确定是否可以添加基于倒顶的癌症复发的批判性终点 癌症登记。